Everything below concerns GIP receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
In August 2020, British and American officials stated that the Gam-COVID-Vac vaccine would likely be rejected due to concerns that the normally rigorous process of vaccine clinical testing was not followed. As of December 2020, Belarus and Argentina granted emergency use authorization for the vector-based vaccine. On 21 January 2021, Hungary became the first European Union country to register the shot for emergency use, as well as the United Arab Emirates in the Persian Gulf region. On 19 January 2021, the Russian authorities applied for the registration of Sputnik V in the European Union, according to the RDIF. On 10 February, the European Medicines Agency (EMA) said that they had "not received an application for a rolling review or a marketing authorisation for the vaccine". The developers have only expressed their interest that the vaccine be considered for a rolling review, but EMA's Human Medicines Committee (CHMP) and the COVID-19 EMA pandemic Task Force (COVID-ETF) need to give their agreement first before developers can submit their application for initiation of the rolling review process. On 4 March 2021, the Committee for Medicinal Products for Human Use (CHMP) of the EMA started a rolling review of Sputnik V. The EU applicant is R-Pharm Germany GmbH, a subsidiary of the Russian R-Pharm. On 16 June, Reuters reported that approval of Sputnik V will be delayed at least until September because not all the necessary clinical data has been submitted by the deadline.
== Proton-coupled amino acid transporters 1 and 2 == The molecular weight of Proton-coupled amino acid transporter 1 is 53.28 kDA; the molecular weight of Proton-coupled amino acid transporter 2 is 53.22 kDA. PAT1 has been found in lysosomes in brain neurons but also in the apical membrane of intestinal epithelial cells where it is associated with the brush border. Proton-coupled amino acid transporter 1 has a higher affinity for proline than it does for glycine and alanine Proton-coupled amino acid transporter 2 is found subcellularly in the kidneys, lungs, spinal cord, and brain and likely has a role in myelinating neurons. It has an overall higher affinity for glycine, alanine, and proline than PAT1 but is more specific for what can inhibit it.
The upper town is composed of three parts: the "coast", the suburban districts of the plateau, and large peripheral housing estates. The neighbourhoods on the "coast" (the Dead Cliff) are residential – more prosperous in the western part (Les Ormeaux, Rue Felix Faure) and more modest to the east (St. Cecilia, Aplemont). The Jenner tunnel passes under the "coast" and connects the upper town to the lower town. It is also on the coast that there are two fortifications of the city, Forts Sainte-Adresse and Tourneville, and the main cemetery (Sainte-Marie cemetery). With the demise of the military functions of the city, the forts are gradually being converted: Fort Sainte-Adresse houses the Hanging Gardens and Fort Tourneville hosted the Tetris project in 2013 – an axis of contemporary music with concert halls and rehearsal studios. To the north of the "coast" suburban districts such as Rouelles, Sainte-Cecile, la Mare au Clerc, Sanvic, Bleville, and Dollemard were developed during the first half of the 19th century. In their extension North-west between Bleville and Octeville airport a new area is being developed: "Les Hauts de Bleville". This eco-district made up of housing units to HQE standards, a Joint Development Area (ZAC), and a school should have a total of 1,000 housing units. The peripheral suburbs of the commune grew in the postwar period. These are large housing estates in Caucriauville, Bois de Bleville, Mont-Gaillard, and Mare-rouge where a disadvantaged population is concentrated.
Sulfite reductase (NADPH) (EC 1.8.1.2, sulfite (reduced nicotinamide adenine dinucleotide phosphate) reductase, NADPH-sulfite reductase, NADPH-dependent sulfite reductase, H2S-NADP oxidoreductase, sulfite reductase (NADPH2)) is an enzyme with systematic name hydrogen-sulfide:NADP+ oxidoreductase. This enzyme catalises the following chemical reaction:
== Use == So far, biomass-based production of industrial microalgae has been widely applied in the fields from food and feed to high-value chemicals for pharmaceutical and ecological applications. Although the commercial cultivation of microalgae became increasingly popular, only algal biomass is processed to current products, while huge volumes of algae-free media are unexploited in flow through cultures and after biomass harvesting of batch cultures. Medium recycling to save culturing costs faces the big risk of growth inhibition. High volumes of spent media give rise to environmental pollution and cost of water and nutrition supply in cultivation when the media are discarded directly to the environment. Therefore the application of recycling methods motivated by the simultaneous generation of high value products from spent medium bears potential in commercial and environmental perspectives.
Sources: en.wikipedia.org
N0 is the initial quantity of the substance that will decay (this quantity may be measured in grams, moles, number of atoms, etc.), N(t) is the quantity that still remains and has not yet decayed after a time t, t½ is the half-life of the decaying quantity, τ is a positive number called the mean lifetime of the decaying quantity, λ is a positive number called the decay constant of the decaying quantity. The three parameters t½, τ, and λ are directly related in the following way:
=== Calcium-sensing receptor (CaR) === The secretion of parathyroid hormone (PTH) is regulated by the interaction of the calcium-sensing receptor with calcium in the blood. The calcium-sensing receptor is present on the plasma membrane of the chief cells. The CaR is a G protein-coupled receptor, as part of the C family. The CaR is divided into three general domains. These include an NH2-terminal extracellular end, a COOH-terminal intracellular end, and seven transmembrane domains. The CaR interacts positively with phospholipase C (PLC) and adenylyl cyclase. The CaR includes phosphorylation sites for protein kinase C (PKC) and protein kinase A (PKA). The phosphorylation of the PLC is seen to inhibit the secretion of PTH due to high calcium levels in the blood. The function of the PKA sites is currently unknown.
== Calibration == Historically, a sucrose solution with a defined concentration was used to calibrate polarimeters relating the amount of sugar molecules to the light polarization rotation. The International Commission for Uniform Methods of Sugar Analysis (ICUMSA) played a key role in unifying analytical methods for the sugar industry, set standards for the International Sugar Scale (ISS) and the specifications for polarimeters in sugar industry. However, sugar solutions are prone to contamination and evaporation. Moreover, the optical rotation of a substance is very sensitive to temperature. A more reliable and stable standard was found: crystalline quartz which is oriented and cut in a way that it matches the optical rotation of a normal sugar solution, but without showing the disadvantages mentioned above. Quartz (silicon dioxide, SiO2) is a common mineral, a trigonal chemical compound of silicon and oxygen. Nowadays, quartz plates or quartz control plates of different thickness serve as standards to calibrate polarimeters and saccharimeters. In order to ensure reliable and comparable results, quartz plates can be calibrated and certified by metrology institutes. Alternatively, calibration may be checked using a Polarization Reference Standard, which consists of a plate of quartz mounted in a holder perpendicular to the light path. These standards are available, traceable to NIST, by contacting Rudolph Research Analytical, located at 55 Newburgh Road, Hackettstown, NJ 07840, USA.
Ligaments are composed of two different tissues: white and yellow. The white fibrous tissues are not stretchy, but are extremely strong so that even if the bone were fractured the tissue would remain in place. The white tissue allows subjective freedom of movement. The yellow elastic tissue can be stretched considerably and return to its original length.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.